Last reviewed · How we verify
Yasmin 20
Yasmin 20 is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol and drospirenone, a progestin with antimineralocorticoid activity.
Yasmin 20 is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol and drospirenone, a progestin with antimineralocorticoid activity. Used for Contraception, Acne vulgaris (in females seeking contraception), Premenstrual dysphoric disorder (PMDD).
At a glance
| Generic name | Yasmin 20 |
|---|---|
| Sponsor | Bayer |
| Drug class | Oral contraceptive (combined estrogen-progestin) |
| Target | Progesterone receptor, estrogen receptor, mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | Phase 3 |
Mechanism of action
The ethinyl estradiol component suppresses the luteinizing hormone (LH) surge needed for ovulation, while drospirenone provides progestational activity and has antimineralocorticoid properties that may help reduce water retention and bloating. The combination also thickens cervical mucus and alters the endometrium to prevent fertilization and implantation.
Approved indications
- Contraception
- Acne vulgaris (in females seeking contraception)
- Premenstrual dysphoric disorder (PMDD)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS (NA)
- Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants (PHASE1)
- E4/DRSP Ovarian Function Inhibition Study (PHASE2)
- YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China (PHASE4)
- The Effect of Oral Contraceptive Pills On Eyes (PHASE4)
- Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri (EARLY_PHASE1)
- Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome (PHASE3)
- Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yasmin 20 CI brief — competitive landscape report
- Yasmin 20 updates RSS · CI watch RSS
- Bayer portfolio CI